NewLimit valuation, funding and investors
NewLimit works in epigenetic reprogramming medicine development, based in South San Francisco, United States. Founded in 2022, it has about 64 employees.
- Last round
- Series C · $435M · Jun 2026
- Valuation at last round
- $3.10B
- Headcount
- 64 · growing
- Grade
- A
- Founded
- 2022
NewLimit valuation today
VCMC values NewLimit at $3.5B today, with a range of $2.7B to $4.9B and a grade of A. The valuation starts from its last funding round, a Series C round in Jun 2026.
Valuation by date (63 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2022 | $19.0M | $6.92M – $52.2M | $20.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $19.2M | $6.97M – $52.6M | $20.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2022 | $19.3M | $7.02M – $53.0M | $21.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2022 | $19.4M | $7.07M – $53.4M | $21.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2022 | $19.6M | $7.12M – $53.8M | $21.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2022 | $19.7M | $7.18M – $54.2M | $21.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2022 | $19.9M | $7.23M – $54.6M | $21.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2022 | $20.0M | $7.28M – $55.0M | $21.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Sep 2022 | $20.2M | $7.34M – $55.4M | $22.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Oct 2022 | $20.3M | $7.39M – $55.8M | $22.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Nov 2022 | $17.9M | $6.52M – $49.2M | $19.6M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 Dec 2022 | $18.0M | $6.57M – $49.6M | $19.7M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 Jan 2023 | $18.2M | $6.62M – $49.9M | $19.9M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 Feb 2023 | $18.3M | $6.67M – $50.3M | $20.0M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 Mar 2023 | $18.4M | $6.71M – $50.6M | $20.1M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 Apr 2023 | $18.6M | $6.76M – $51.0M | $20.3M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 May 2023 | $18.7M | $6.81M – $51.4M | $20.4M (+9%) | before first round | 7 | unknown | D | 0% |
| 17 May 2023 | $223M | $146M – $609M | $400M (+80%) | after a round | 7 | unknown | C | 0% |
| 1 Jun 2023 | $228M | $146M – $609M | $400M (+75%) | after a round | 7 | unknown | C | 0% |
| 1 Jul 2023 | $239M | $146M – $609M | $400M (+67%) | after a round | 7 | unknown | C | 0% |
| 1 Aug 2023 | $252M | $146M – $609M | $400M (+59%) | after a round | 7 | unknown | C | 0% |
| 1 Sep 2023 | $264M | $146M – $609M | $400M (+51%) | after a round | 7 | unknown | C | 0% |
| 1 Oct 2023 | $277M | $146M – $609M | $400M (+44%) | after a round | 19 | growing | C | 0% |
| 1 Nov 2023 | $292M | $146M – $609M | $400M (+37%) | after a round | 19 | growing | C | 0% |
| 1 Dec 2023 | $306M | $146M – $609M | $400M (+31%) | after a round | 19 | growing | C | 0% |
| 1 Jan 2024 | $322M | $146M – $609M | $400M (+24%) | after a round | 19 | growing | C | 0% |
| 1 Feb 2024 | $346M | $151M – $629M | $413M (+19%) | after a round | 22 | growing | C | 0% |
| 1 Mar 2024 | $372M | $155M – $647M | $425M (+14%) | after a round | 25 | growing | C | 0% |
| 1 Apr 2024 | $393M | $155M – $647M | $425M (+8%) | after a round | 25 | growing | C | 0% |
| 1 May 2024 | $414M | $155M – $647M | $425M (+3%) | after a round | 25 | growing | C | 0% |
| 1 Jun 2024 | $425M | $154M – $647M | $425M (0%) | after a round | 25 | up | C | 0% |
| 1 Jul 2024 | $432M | $161M – $658M | $432M (0%) | after a round | 27 | growing | C | 0% |
| 1 Aug 2024 | $439M | $166M – $668M | $439M (0%) | after a round | 29 | growing | C | 0% |
| 1 Sep 2024 | $439M | $169M – $668M | $439M (0%) | after a round | 29 | growing | C | 0% |
| 1 Oct 2024 | $439M | $171M – $668M | $439M (0%) | after a round | 29 | growing | C | 0% |
| 1 Nov 2024 | $452M | $178M – $687M | $452M (0%) | after a round | 33 | growing | C | 0% |
| 1 Dec 2024 | $452M | $181M – $687M | $452M (0%) | after a round | 33 | growing | C | 0% |
| 1 Jan 2025 | $455M | $185M – $692M | $455M (0%) | after a round | 34 | growing | C | 0% |
| 1 Feb 2025 | $455M | $187M – $692M | $455M (0%) | after a round | 34 | growing | C | 0% |
| 1 Mar 2025 | $455M | $190M – $692M | $455M (0%) | after a round | 34 | growing | C | 0% |
| 1 Apr 2025 | $455M | $192M – $692M | $455M (0%) | after a round | 34 | growing | C | 0% |
| 1 May 2025 | $455M | $195M – $692M | $455M (0%) | after a round | 34 | growing | C | 0% |
| 7 May 2025 | $823M | $579M – $1.7B | $1.2B (+50%) | after a round | 34 | growing | B | 0% |
| 1 Jun 2025 | $846M | $579M – $1.7B | $1.2B (+46%) | after a round | 34 | growing | B | 0% |
| 1 Jul 2025 | $875M | $579M – $1.7B | $1.2B (+41%) | after a round | 38 | growing | B | 0% |
| 1 Aug 2025 | $905M | $579M – $1.7B | $1.2B (+36%) | after a round | 38 | growing | B | 0% |
| 1 Sep 2025 | $937M | $579M – $1.7B | $1.2B (+32%) | after a round | 38 | growing | B | 0% |
| 1 Oct 2025 | $979M | $595M – $1.8B | $1.3B (+29%) | after a round | 43 | growing | B | 0% |
| 21 Oct 2025 | $1.6B | $1.4B – $2.0B | $1.8B (+10%) | after a round | 43 | growing | A | 0% |
| 1 Nov 2025 | $1.6B | $1.4B – $2.0B | $1.8B (+10%) | after a round | 43 | growing | A | 0% |
| 1 Dec 2025 | $1.6B | $1.4B – $2.1B | $1.8B (+11%) | after a round | 47 | growing | A | 0% |
| 1 Jan 2026 | $1.7B | $1.4B – $2.1B | $1.8B (+10%) | after a round | 48 | growing | A | 0% |
| 1 Feb 2026 | $1.7B | $1.4B – $2.1B | $1.8B (+9%) | after a round | 48 | growing | A | 0% |
| 1 Mar 2026 | $1.7B | $1.4B – $2.1B | $1.8B (+9%) | after a round | 50 | growing | A | 0% |
| 1 Apr 2026 | $1.7B | $1.4B – $2.1B | $1.8B (+7%) | after a round | 50 | growing | A | 0% |
| 1 May 2026 | $1.7B | $1.4B – $2.1B | $1.9B (+7%) | after a round | 52 | growing | A | 0% |
| 1 Jun 2026 | $1.8B | $1.4B – $2.1B | $1.9B (+5%) | after a round | 52 | growing | A | 0% |
| 3 Jun 2026 | $3.1B | $2.7B – $4.6B | $4.0B (+30%) | after a round | 52 | growing | A | 0% |
| 1 Jul 2026 | $3.2B | $2.7B – $4.6B | $4.0B (+27%) | after a round | 52 | growing | A | 0% |
| 1 Aug 2026 | $3.2B | $2.7B – $4.7B | $4.1B (+26%) | after a round | 55 | growing | A | 0% |
| 1 Sep 2026 | $3.3B | $2.7B – $4.7B | $4.1B (+23%) | after a round | 55 | growing | A | 0% |
| 1 Oct 2026 | $3.4B | $2.7B – $4.9B | $4.2B (+23%) | after a round | 64 | growing | A | 0% |
| 24 Oct 2026 | $3.5B | $2.7B – $4.9B | $4.2B (+21%) | after a round | 64 | growing | A | 0% |
Key facts about NewLimit
- Founded
- 2022
- Headquarters
- South San Francisco, United States
- Employees
- about 64 +49% in a year
- Total raised
- $650M
- Funding rounds
- 4
- Last round
- Series C Jun 2026
NewLimit was founded in 2022 by Blake Byers, Brian Armstrong, Greg Johnson and Jacob Kimmel.
NewLimit funding history
NewLimit has 4 funding rounds on record, from May 2023 to Jun 2026, $650M in total. The latest disclosed valuation is $3.10B post-money (Series C, Jun 2026).
Series C 2 Jun 2026
Led by Founders Fund; with Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor, Eli Lilly Ventures, Human Capital.
Sources: blog.newlimit.com, finance.yahoo.com, statnews.com and 4 more
$435M
$3.10B post-money
Growth Equity 20 Oct 2025
Led by Eli Lilly and Company; with Duke Management Co, Section 32, Abstract, Kleiner Perkins, Dimension, Human Capital, Boost VC, Lilly Ventures, GreatThings, Kivu Ventures, Mangusta Capital, NFDG.
Sources: blog.newlimit.com, blog.newlimit.com, ventureburn.com and 3 more
$45M
$1.62B post-money
Series B 6 May 2025
Led by Kleiner Perkins; with Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, Valor, Dimension, Founders Fund, Brian Armstrong.
Sources: blog.newlimit.com, fiercebiotech.com, techcrunch.com and 2 more
$130M
Series A 16 May 2023
With Dimension, Founders Fund, Kleiner Perkins.
Sources: pharmaphorum.com, blog.newlimit.com, axios.com and 2 more
$40M
NewLimit investors
22 investors have backed NewLimit; Kleiner Perkins, Founders Fund and Eli Lilly and Company led at least one round.
- Kleiner Perkins lead, 4 rounds
- Founders Fund lead, 3 rounds
- Eli Lilly and Company lead
- Abstract 2 rounds
- Nat Friedman/Daniel Gross 2 rounds
- Valor 2 rounds
- Brian Armstrong
- Duke Management Co
- Eli Lilly Ventures
- GreatThings
- Greenoaks
- Khosla Ventures
- Lilly Ventures
- NFDG
- Section 32
- Thrive Capital
What NewLimit does
NewLimit works in biotechnology, with 14 recorded offerings and customers in healthcare.
NewLimit is a biotechnology company engaged in the development of epigenetic reprogramming medicines for the treatment of age-related diseases, with a focus on the liver, immune, and vascular systems. The company utilizes technologies such as single cell genomics, machine learning, and high-throughput functional assays to discover rejuvenating interventions. NewLimit also conducts research and development in cell biology, genomics, computational biology, and operations, and collaborates across disciplines to advance its therapeutic approaches.
Description from Veridion's company data.
Products and services
- Epigenetic Reprogramming Medicine Development
- Age-Related Disease Treatment Development
- Liver Disease Therapeutic Development
- Immune System Therapeutic Development
- Vascular Disease Therapeutic Development
- Epigenetic Aging Biology Research
- Functional Genomics Research
- Pooled Perturbation Screening Research
- Machine Learning Model Development
- Single Cell Genomics Research
- High-Throughput Functional Assay Development
- Regenerative Potential Restoration Research
- Experimental Intervention Design Services
- Healthspan Extension Research
Markets
- Healthcare
Technology
- Epigenetic Reprogramming
- Single Cell Genomics
- Machine Learning
- High-Throughput Functional Assays
- Pooled Perturbation Screening
Business model
- Manufacturing
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about NewLimit
What is NewLimit worth?
Valuation $3.5B (range $2.7B to $4.9B), as of 24 Oct 2026. The last disclosed valuation was $3.10B (Series C, Jun 2026).
Has NewLimit raised money?
NewLimit has 4 funding rounds on record, from May 2023 to Jun 2026, $650M in total. The latest disclosed valuation is $3.10B post-money (Series C, Jun 2026).
Who has invested in NewLimit?
Kleiner Perkins, Founders Fund, Eli Lilly and Company, Dimension, Human Capital and Abstract, and 16 more. Lead investors include Kleiner Perkins, Founders Fund and Eli Lilly and Company.
How many people work at NewLimit?
About 64, up 49% over the last year. Headcount grew from 7 in Nov 2022 to 64 in Sep 2026.
What does NewLimit do?
NewLimit works in biotechnology, with 14 recorded offerings and customers in healthcare. Its main offerings are epigenetic reprogramming medicine development, age-related disease treatment development and liver disease therapeutic development.
When was NewLimit founded, and where is it based?
NewLimit was founded in 2022 and is based in South San Francisco, United States. It has about 64 employees, up 49% over the last year.